Attention and clinical symptoms in schizophrenia

Psychiatric Quarterly

Volumn 68, Issue 4, 1997, Pages 343-359

  Cornblatt, Barbara ^a   Obuchowski, Michael ^a   Schnur, David B ^b,c   O'Brien, John D ^b,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ELMHURST HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER; COGNITION; CONFERENCE PAPER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0030728246     PISSN: 00332720     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025495030997     Document Type: Conference Paper

References (50)

1. Wohlberg GW, Kornetsky C: Sustained attention in remitted schizophrenics. Archives of General Psychiatry 28:533-537, 1973.
2. Asarnow RF, MacCrimmon D: Residual performance deficit in clinically remitted schizophrenics: A marker of schizophrenia? Journal of Abnormal Psychology 87:597-608, 1978.
3. Mussgay L, Hertwig R: Signal detection indices in schizophrenics on a visual, auditory and bimodal Continuous Performance Test. Schizophrenia Research 3:303-310, 1990.
4. Cornblatt B, Erlenmeyer-Kimling L: Global attentional deviance as a marker of risk for schizophrenia: Specificity and predictive validity. Journal of Abnormal Psychology 94:470-485, 1985.
5. Lees Roitman SE, Cornblatt BA, Bergman A, et al: Attentional functioning in schizotypal personality disorder. American Journal of Psychiatry, 154:655-660, 1997.
6. Cornblatt BA, Lenzenweger MF, Dworkin RH, et al: Childhood attentional dysfunctions predict social deficits in unaffected adults at risk for schizophrenia. British Journal of Psychiatry 161:59-64, 1992.
7. Cornblatt BA, Keilp JG: Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophrenia Bulletin 20:31-46, 1994.
8. Erlenmeyer-Kimling L, Cornblatt B: The New York High Risk Project: A Follow up Report. Schizophrenia Bulletin 13:451-461, 1987.
9. Andreasen NC: Negative symptoms in schizophrenia. Archives of General Psychiatry 39:784-788, 1982.
10. Nuechterlein KH, Edell WS, Norris M, et al: Attentional vulnerability indicators, thought disorder and negative symptoms. Schizophrenia Bulletin 12:408-426, 1986.
11. Pandurangi AK, Kenji WS, Pelonero AL, et al: Sustained attention and positive formal thought disorder in schizophrenia. Schizophrenia Research 13:109-116, 1994.
12. Strauss ME, Buchanan RW, Hale J: Relations between attentional deficits and clinical symptoms in schizophrenic outpatients. Psychiatry Research 74:205-213, 1993.
13. Earle-Boyer EA, Serper MR, Davidson M, et al: Continuous performance tests in schizophrenic patients: Stimulus and medication effects on performance. Psychiatry Research 37:47-56, 1991.
14. Nestc PG, Fauz SF, McCarley RW, et al: Neuroleptics improve sustained attention in schizophrenia: A study using signal detection theory. Neuropsychopharmacology 4:145-149, 1991.
15. Orzack MH, Kornetsky C, Freemen H: The effects of daily administration of carphenazine on attention in the schizophrenic patient. Psychopharmacologia 11:31-38, 1967.
16. Serper MR, Bergman RL, Harvey PD: Medication may be required for the development of automatic information processing in schizophrenia. Psychiatry Research 32:281-288, 1990.
17. Spohn HE, Lacoursiere RB, Thompson K, et al: Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics. Archives of General Psychiatry 34:633-643, 1977.
18. Cannon TD, Mednick SA, Parnes J: Antecedents of predominantly negative-and predominantly positive-symptom schizophrenia in a high-risk population. Archives of General Psychiatry 47:622-632, 1990.
19. Saykin AJ, Shtasel DL, Gur RE, et al: Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Archives of General Psychiatry 51:124-131, 1994.
20. Seidman LJ, Pepple JR, Faraone SV, et al: Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biological Psychiatry 33:575-584, 1993.
21. Serafetinides EA, Collins S, Clark ML: Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Journal of Nervous and Mental Disease 154:31-42, 1972.
22. Walker E: Attentional and neuromotor functions in schizophrenics, schizoaffectives, and patients with other affective disorders. Archives of General Psychiatry 38:1344-1358, 1981.
23. Walker E, Green M: Motor proficiency and attentional task performance by psychotic patients. Journal of Abnormal Psychology 91:261-268, 1982.
24. Walker E, Shaye J: Familial schizophrenia: A predictor of neuromotor and attentional abnormalities in schizophrenia. Archives of General Psychiatry 39:1153-1156, 1982.
25. Medalia A, Gold J, Merriam A: The effects of neuroleptics on neuropsychological test results of schizophrenics. Archives of Clinical Neuropsychology 3:249-271, 1988.
26. Cornblatt B, Erlenmeyer-Kimling L: Global attentional deviance as a marker of risk for schizophrenia: Specificity and predictive validity. Journal of Abnormal Psychology 94:470-485, 1985.
27. Erlenmeyer-Kimling L, Cornblatt B: The New York High Risk Project: A Follow up Report. Schizophrenia Bulletin 13:451-461, 1987.
28. Mirsky AF, Kugelmass S, Ingraham LJ, et al: Overview and summary: 25 year follow-up of high risk children. Schizophrenia Bulletin 21:227-239, 1995.
29. Cornblatt BA, Lenzenweger M, Erlenmeyer-Kimling L: The Continuous Performance Test-Identical Pairs (CPT-IP): II. Contrasting profiles of attentional deficits in schizophrenic and depressed patients. Psychiatry Research 29:65-85, 1989.
30. Winters L, Cornblatt BA, Erlenmeyer-Kimling L: The prediction of psychiatric disorders in late adolescence, in Schizophrenia: A life-Course Developmental Perspective. Edited by Walker E. New York, Academic Press, 1991.
31. Cornblatt B, Obuchowski M, O'Brien JD, Siever L: Are attentional deficits independent of clinical symptoms in schizophrenia? American Congress of Neuropsychopharmacology, Annual Meeting, San Juan, Puerto Rico, December 9-13, 1996.
32. Dworkin RH, Green SR, Small NE, et al: Positive and negative symptoms and social competence in adolescents at risk for schizophrenia and affective disorder. American Journal of Psychiatry 147:1234-1236, 1990.
33. Erlenmeyer-Kimling L, Cornblatt BA, Bassett AS, et al: High-risk children in adolescence and young adulthood: Course of global adjustment, in Straight and Devious Pathways from Childhood to Adulthood. Edited by Robins L, Rutter M. Cambridge, Cambridge University Press, 1990.
34. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 153:321-330, 1996.
35. American Psychiatric Association: DSM-III-R: Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington, D.C., American Psychiatric Press, 1987.
36. Andreasen NC: Comprehensive assessment of symptoms and history. University of Iowa College of Medicine, Iowa City, 1987.
37. Orvaschel H, Puig-Antich J: Schedule for affective disorder and schizophrenia for school-age children. Epidemiologic version. Medical College of Pennsylvania, Philadelphia, 1987.
38. Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry 44:660-669, 1987.
39. Cornblatt B, Obuchowski M: Update of high risk research: 1987-1997. International Review of Psychiatry, In press.
40. Cornblatt BA, Rish N, Fans G, et al: The Continuous Performance Test-Identical Pairs (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Research 26:223-238, 1988.
41. Neuchterlein KH: Vigilance in schizophrenia and related disorders, in Handbook of Schizophrenia: Neuropsychology, Psychophysiology and Information Processing, vol. 5. Edited by Steinhauer S, Zubin J, Gruzelier JH. Amsterdam, Elsevier Science Publishers, 1991.
42. Rutschmann J, Cornblatt B, Erlenmeyer-Kimling L: Sustained attention in children at risk for schizophrenia. Archives of General Psychiatry 34:571-575, 1977.
43. Orzack MH, Kornetsky C: Attention dysfunction in chronic schizophrenia. Archives of General Psychiatry 14:323-326, 1966.
44. Orzack MH, Kornetsky C: Environmental and familial predictors of attention behavior in chronic schizophrenics. Journal of Psychiatric Research 9:21-35, 1971.
45. Kay SR, Opler LA, Fiszbein A: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13:261-276, 1987.
46. StatSoft, Inc: STATISTICA for Windows (Computer program manual). Tulsa, StatSoft, Inc., 1995.
47. Murray RM, O'Callaghan E, Castle DJ, et al: A neurodevelopmental approach to the classification of schizophrenia. Schizophrenia Bulletin 18:319-332, 1992.
48. Cannon TD, Zorrilla LE, Shtasel D, et al: Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Archives of General Psychiatry 51: 651-661, 1994.
49. Borison RL, Pathiraja AP, Diamond BI, et al: Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin 28:213-218, 1992.
50. Lehman AF, Thompson JW, Dixon LB, et al: Schizophrenia: Treatment outcomes research-editors' introduction. Schizophrenia Bulletin 21:561-566, 1995.